my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Our goal is to make chronic illnesses which occur in recurring attacks or episodes controllable for those affected. Alongside the development of software algorithms for the early recognition of attacks, we are working on mobile therapy methods for sufferers. Our first product is the headache and mig more
When migraine sufferers see the tell-tale squiggly lines, light flashes and blind spots of a migraine aura, they prepare for a migraine. When researchers see the brain image of an aura, they try to figure out what causes it and if there is a way to stop the start of the migraine. Now an internationa more
Of the more than 38 million Americans who experience migraine headaches, 28 million are women. Compared to men, women also experience more frequent and severe migraines and don't respond as well to drug treatments. Findings from a new study conducted in rats reveal that females may be more susceptib more
For some medical complaints, open-label placebos work just as well as deceptive ones. As psychologists from the University of Basel and Harvard Medical School report in the journal Pain, the accompanying rationale plays an important role when administering a placebo. The successful treatment of cert more
SCI COMMUNIn science news around the world, the U.S. Food and Drug Administration approves the first drug to prevent migraine headaches. Swedish universities and research institutes cancel their contract with academic publishing giant Elsevier after seeking "sustainable" pricing and open access to a more
Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related more
Nature Biotechnology 36, 207 (2018). doi:10.1038/nbt0318-207 Author: Elie Dolgin more
Watchlist
This is where you can add this topic to your personal favourites
© 1997-2019 LUMITOS AG, All rights reserved
